Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Pighi C, Cheong TC, Compagno M, Patrucco E, Arigoni M, Olivero M, Wang Q, López C, Bernhart SH, Grande BM, Poggio T, Langellotto F, Bonello L, Dall'Olio R, Martínez-Martín S, Molinaro L, Francia di Celle P, Whitfield JR, Soucek L, Voena C, Calogero RA, Morin RD, Staudt LM, Siebert R, Zamò A, Chiarle R.
Pighi C, et al. Among authors: bonello l.
Blood Adv. 2021 Dec 14;5(23):5239-5257. doi: 10.1182/bloodadvances.2021005682.
Blood Adv. 2021.
PMID: 34625792
Free PMC article.